MARKET

RVNC

RVNC

Revance Therapeu
NASDAQ
3.570
-0.090
-2.46%
After Hours: 3.710 +0.14 +3.92% 17:10 04/24 EDT
OPEN
3.640
PREV CLOSE
3.660
HIGH
3.750
LOW
3.539
VOLUME
1.79M
TURNOVER
0
52 WEEK HIGH
37.98
52 WEEK LOW
3.539
MARKET CAP
372.05M
P/E (TTM)
-0.9322
1D
5D
1M
3M
1Y
5Y
Barclays Sticks to Their Buy Rating for Revance Therapeutics (RVNC)
TipRanks · 1d ago
OPI, RVNC and AQST are among after hour movers
On the Move OPI, RVNC and AQST are among after hour movers. Cadence Design Systems and Synopsys are among the companies losing ground. Oportun Financial and Humacyte are the biggest gainers in this week's list of names on the move.
Seeking Alpha · 2d ago
Weekly Report: what happened at RVNC last week (0415-0419)?
Weekly Report · 2d ago
AbbVie working with FDA after reports of fake Botox versions
Seeking Alpha · 04/16 14:47
Weekly Report: what happened at RVNC last week (0408-0412)?
Weekly Report · 04/15 10:49
Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting
Revance Therapeutics, Inc. Will present two poster presentations on DAXXIFY® for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology in 2024. A new analysis from ASPEN trials shows 50% of peak efficacy remained at the time of request for early retreatment. A second abstract examines the influence of DAXXify's formulation on clinical performance. The long-acting symptom control allows physicians to customize treatment intervals.
Benzinga · 04/12 12:01
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
Shares of BlackBerry Limited jumped 9% to $3.1340 on Tuesday. The company announced a collaboration with Advanced Micro Devices, Inc. The Dow Jones index fell over 200 points in today’s session. Other big U.S. Stocks were also lower.
Benzinga · 04/09 14:43
Weekly Report: what happened at RVNC last week (0401-0405)?
Weekly Report · 04/08 10:53
More
About RVNC
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Webull offers Revance Therapeutics Inc stock information, including NASDAQ: RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.